Treatment to Regress to Normoglycemia in Women With a Recent History of

Status Recruiting

Clinical Trial Summary

The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.

Clinical Trial Description

The diagnosis of gestational diabetes mellitus (GDM) during pregnancy identifies young women with abnormalities in pancreatic beta cell function that worsen over time, leading to diabetes. It is estimated that between 15% and 70% of women with a history GDM will progress to type 2 diabetes mellitus (T2DM). However, upon an impaired glucose tolerance test result in the early postpartum period, the American College of Obstetricians and Gynecologists only recommend considering referral for management, weight loss and physical activity counseling, considering metformin if testing results are severe enough, and yearly assessment of glycemic status. In many cases, it is possible to reverse diabetes by losing weight in the early stages before permanent, systemic damage occurs. Therefore, there is a dire need for efficacious pharmacologic intervention options in this period of postpartum diabetes recovery to return women to normoglycemia and lower future T2DM risk. Weight loss and medications that mitigate impairments in insulin secretion show the best promise for delaying or preventing T2DM, the dominant form of diabetes that develops after GDM. The primary study objective is "to examine the efficacy of semaglutide 1mg compared to placebo on regression to normoglycemia in women with dysglycemia and a recent history of gestational diabetes mellitus (i.e., 6-36 months postpartum)" to answer the research question of: "Among women with dysglycemia and a recent history of gestational diabetes mellitus, can acute treatment of semaglutide 1mg lead to regression to normoglycemia?" ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04873050
Study type	Interventional
Source	Woman's
Contact	Donna Shaler, BS
Phone	225-231-5268
Email	Donna.Shaler@womans.org
Status	Recruiting
Phase	Phase 4
Start date	January 13, 2022
Completion date	August 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05052918` - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes	N/A
Completed	`NCT03714646` - Beta Glucan and Acetate Production	N/A
Completed	`NCT03377244` - Healthy Body Healthy Souls in the Marshallese Population	N/A
Completed	`NCT04427982` - Dance and Diabetes/Prediabetes Self-Management	N/A
Recruiting	`NCT05008276` - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed	`NCT03480022` - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS	Phase 3
Active, not recruiting	`NCT05290233` - Time Restricted Eating Plus Exercise for Weight Management	N/A
Withdrawn	`NCT05726409` - Mobile Application to Create Healthy Food Preparation Habits for Patients With Diabetes and Prediabetes	N/A
Completed	`NCT02834078` - Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome	N/A
Completed	`NCT04902326` - Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)	N/A
Recruiting	`NCT04168372` - Fructose: Substrate, Stimulus, or Both?	N/A
Completed	`NCT03272074` - Egg Consumption and Glycemic Control in Individuals With Pre- and Type II-diabetes	N/A
Not yet recruiting	`NCT05939349` - A Prescription for Health Equity: A Healthcare Provider-based Produce Prescription Program for People With Prediabetes and Type 2 Diabetes	N/A
Completed	`NCT04978376` - TRE With Physical Activity for Weight Management	N/A
Recruiting	`NCT03997656` - A Digital Therapy for Diabetes Prevention Among Overweight Adults in Terengganu, Malaysia	N/A
Recruiting	`NCT05166785` - BRInging the Diabetes Prevention Program to GEriatric Populations	N/A
Completed	`NCT01729078` - Dietary Interventions in Prediabetes	N/A
Completed	`NCT04507685` - Asian Indian Prediabetes Study	N/A
Completed	`NCT03292315` - Once Weekly GLP-1 in Persons With Spinal Cord Injury	Phase 4
Active, not recruiting	`NCT05353790` - Dietary Exchanges With Avocado and Mango in Pre-diabetes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treatment to Regress to Normoglycemia in Women With a Recent History of GDM — SWEET

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms